FOMX News and Press, Foamix Pharmaceuticals Ltd. From 11/03/19

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 129 weeks of public selections as part of this ongoing live forward-testing. ...

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in ...

Foamix Pharmaceuticals ( FOMX ) announced that the FDA had accepted its application for review of its topical foam drug FMX103 to treat patients with moderate-to-severe papulopustular rosacea in adults. This opens up the opportunity for the biotech to possibly receive approval for this l...

Foamix Pharmaceuticals (NASDAQ: FOMX ) inks an agreement with ASM Aerosol-Service for the manufacture and supply of AMZEEQ (minocycline) topical foam, 4%, approved by the FDA last week for acne vulgaris, and FMX103 (minocycline) topical foam, 1.5% for the potential treatment of papulopus...

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a long term contract manufacturing and su...

Foamix Pharmaceuticals (NASDAQ: FOMX ), together with licensee LEO Pharma A/S, has settled  patent infringement litigation with an affiliate of Teva Pharmaceutical Industries (NYSE: TEVA ) regarding topical rosacea med Finacea Foam. Financial details remain confidential. More news on...

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it...

AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or t...

AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or t...

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announc...